Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02200003 · ClinicalTrials.gov registry record · Phase 2

Attention Bias Modification for Anxiety: A Randomized Control Trial With Biomarkers

A Phase 2 study, sponsored by Hunter College of City University of New York.

Completed
Registry status
Phase 2
Development phase
100
Enrollment target

NCT02200003 is a Phase 2 study that has completed, run by Hunter College of City University of New York. The registered enrollment target is 100 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02200003, a Phase 2 study, has completed, sponsored by Hunter College of City University of New York.

COMPLETED
Registry status
Phase 2
Development phase
100 participants
Enrollment target

Study Summary

Computer-based attention bias modification treatment (ABMT), which is brief, cost-effective, and easy to administer, targets a key mechanism in pathological anxiety - the threat bias, or exaggerated attention feared or threatening stimuli. It remains unclear how and for whom ABMT is effective, limiting clinical translation. The proposed research involves an RCT using a highly sensitive measure of neurocognitive functioning, scalp-recorded event-related potentials (ERPs), to delineate key mechanisms of an emerging treatment for anxiety. Researchers will recruit 90 anxious participants to engage in the study and pursue the following three specific aims: Aim 1 will examine relations between neural and behavioral responses to threat prior to ABMT. Aim 2 will examine the effects of ABMT on ERPs to threat, threat bias, and anxiety. Aim 3 will examine relations between ERP responses to threat and reductions in threat bias and anxiety. Researchers will test whether post-training neural changes, specified in Aim 2, are associated with reductions in behavioral threat bias and anxiety severity. Researchers will also explore whether ERP measures of greater attention capture and/or reduced control of attention to threat at baseline predict treatment response, helping identify which patients will benefit most from ABMT. Through the innovative combination of a highly sensitive neurocognitive measure and an RCT design, this study aims to delineate core neurocognitive responses to threat as mechanisms in the remediation of anxiety. Confirmation of study hypotheses would, ultimately, accelerate the pace of development of more biologically-informed, accessible, and targeted interventions for anxiety.

Interventions

  • BEHAVIORAL attention bias modification for anxiety

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2015-02
Est. Completion 2018-07
Phase Phase 2

What the Registry Record Tells You About NCT02200003

The ClinicalTrials.gov registry entry for NCT02200003 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hunter College of City University of New York, which has 29 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which attention bias modification for anxiety is the first listed.

NCT02200003 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02200003 about?

NCT02200003 is a clinical study titled "Attention Bias Modification for Anxiety: A Randomized Control Trial With Biomarkers". Computer-based attention bias modification treatment (ABMT), which is brief, cost-effective, and easy to administer, targets a key mechanism in pathological anxiety - the threat bias, or exaggerated attention feared or threatening stimuli. It remains unclear how and for whom ABMT is effective, limit...

What is the current status of trial NCT02200003?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2015-02. Estimated completion is 2018-07.

What interventions are being tested in trial NCT02200003?

The interventions under investigation include: attention bias modification for anxiety (BEHAVIORAL).

Who is sponsoring clinical trial NCT02200003?

This trial is sponsored by Hunter College of City University of New York, which has 29 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.